Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

Celularity announced it has filed its delayed Form 10-K and regained compliance with Nasdaq listing rules, closing the delisting review matter. The company highlighted strategic transformation steps, including the out-license of its biomaterials portfolio and a reduction of liabilities by approximately $13 million.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.